Some investors asked questions on the investor interaction platform: in the medical community, it is mentioned in the code for diagnosis and treatment of gastric cancer (version 2021) issued by the Ministry of health of China that a multi drug combination scheme is adopted for the treatment of gastric cancer. The drugs include capecitabine, cisplatin, oxaliplatin, paclitaxel, docetaxel, albumin paclitaxel, irinotecan (none), epirubicin (can be replaced by epirubicin hydrochloride), etc. Targeted therapeutic drugs include trastuzumab… After inquiry, your company only produces oxaliplatin, nedaplatin, paclitaxel and docetaxel. Do you have any study plans for Zhejiang Hisun Pharmaceutical Co.Ltd(600267) , the only most complete variety of drugs in the anti gastric cancer drug industry
Beijing Aosaikang Pharmaceutical Co.Ltd(002755) (002755. SZ) said on the investor interaction platform on January 17 that the company will actively learn from the valuable experience of the same industry. At present, the company focuses on product R & D, production and sales in the fields of peptic ulcer, tumor, drug-resistant bacterial infection and chronic diseases.
